2024-11-17 23:49:00
Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
Corporate/ 2023-07-24
Everest Medicines Announces China NMPA R...

--Further regulatory support for accelerated approval of Nefecon following NMPA\'s NDA acceptance with Breakthrough Therapy Designation—

Grand Pharma Announces Successful Clinical Progress of its Oral 3CL Protease Inhibitor GS221 Against COVID-19
Corporate/ 2023-07-24
Grand Pharma Announces Successful Clinic...

GS221 has conducted 3 clinical trials. Current results of clinical trials show favorable safety and tolerance in the subjects. After adminis...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release